Wednesday 11 November 2026About PsychregWrite for Us

Health

Broughton Welcomes FDA Approval of ZYN Nicotine Pouches

by Psychreg News Team ·

e-cigarette

Broughton, a prominent contract research organisation specialising in reduced-risk nicotine products, has welcomed the US Food and Drug Administration’s (FDA) authorisation of ZYN nicotine pouches for sale. This milestone underscores the importance of science-driven approaches to tobacco harm reduction while offering adult smokers an alternative to combustible cigarettes.

Nicotine pouches, a type of modern oral nicotine product (MONP), avoid the harmful by-products of combustion, providing a less hazardous option for smokers seeking to quit traditional cigarettes. Despite their promise, the industry faces ongoing challenges in ensuring these products are responsibly marketed and comply with rigorous regulatory standards.

Chris Allen, CEO of Broughton, said: “This FDA authorisation is a significant step forward in tobacco harm reduction, demonstrating the vital role of scientifically validated products in providing consumers with less harmful options. At Broughton, we are committed to supporting the development of innovative nicotine products that can transform public health outcomes.”

With over eight million deaths attributed to smoking-related illnesses annually, reduced-risk products like nicotine pouches offer an opportunity to reshape global health trends. Sweden’s success in achieving a smoke-free status through regulatory balance and alternative products serves as an example of the potential for innovation and harm reduction to drive significant public health improvements.

Broughton has established itself as a trusted partner for nicotine innovators by delivering comprehensive regulatory and scientific consultancy services. The company’s expertise spans toxicological risk assessments, behavioural studies, and regulatory submissions, ensuring that reduced-risk products meet stringent safety and efficacy standards.

Drawing on in-depth knowledge of the FDA’s Premarket Tobacco Product Application (PMTA) process, Broughton offers tailored strategies and has a strong track record of securing PMTA Marketing Orders. This enables manufacturers to confidently bring innovative oral nicotine products to the US market while navigating complex compliance requirements.

For businesses considering PMTA submissions, Broughton provides strategic guidance and regulatory expertise to enhance success rates. The company’s contributions to tobacco harm reduction efforts underscore its commitment to advancing public health through safer nicotine alternatives.